AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...
Novo Nordisk launched "My Ozempic® Era" today, a national campaign which spotlights the longstanding Ozempic® patient ...
Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...
Nearly one-third of adult employees would change jobs in order to gain coverage. As the demand for GLP-1 weight loss ...
Irish Examiner on MSN3d
On the rebound: What are the long-term risks of Ozempic?Ahead of World Obesity Day, we examine the impact of the game-changing drugs that control appetite. Increasingly being taken ...
Outsourcing Facilities Association and North American Custom Laboratories allege the FDA removed semaglutide from its ...
New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising ...
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...
Despite the continued success of GLP-1 drugs Ozempic and Wegovy, Novo Nordisk CEO Lars Fruergaard Jørgensen took a slight pay cut in 2024. He received 57.1 million Danish kroner (DKK) – $8 million – ...
Today we'll look at six European stocks that could continue outperforming in 2025. Some of these companies are available to ...
The FDA recently removed semaglutide from its drug shortage list, which has not been considered commercially available since ...
A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback